



FINANCIAL TEAR SHEET

CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life- improving drugs. For more than 30 years, we’ve been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in ove countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug develop process.

We help change people’s lives for the better every single day. It’s what we are passionate about.

STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$102.52
Change (%)	▲ 1.32 (1.30%)
Volume	145,442
52 Week Low	\$73.07
Market Cap	\$6,569,094,177
Rolling EPS	1.73
PE Ratio	58.6517
Shares Outstanding	64,076,221
Data as of 07/20/18 4:00 p.m. ET	



NEWS & EVENTS

Date	Title
------	-------

Date	Title
------	-------

07/12/18	PRA Health Sciences to Report Second Quarter 2018 Earnings
05/24/18	PRA Named International Clinical Research Company of the Year
05/03/18	PRA Named Clinical Research Company of the Year and Makes the Forbes 2018 America's Best Large Employers List

08/02/18	Q2 2018 PRA Health Sciences
9:00 a.m. ET	Inc Earnings Conference Call

SEC FILINGS

Filing Date	Form
07/02/18	4
07/02/18	3
06/25/18	4
06/25/18	4

BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Alexander G. Dickinson	Director
Linda S. Graiss, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)